Edesa Biotech, Inc.

Dr. Pardeep Nijhawan, through a professional corporation, filed his 11th Schedule 13D amendment reporting beneficial ownership of approximately 7.8% of Edesa Biotech (EDSA) as of August 21, 2026. The total of 1,164,676 shares includes direct common shares, warrants, and preferred shares on an as-converted basis. Nijhawan is a significant affiliated holder at Edesa Biotech, maintaining a meaningful ownership stake that exceeds the 5% Schedule 13D threshold. The amendment likely reflects a change in ownership percentage due to a dilutive equity issuance by the company.

Velan Capital Investment Management LP (Alpharetta, GA) filed its second Schedule 13D amendment for Edesa Biotech (EDSA), reporting aggregate beneficial ownership of approximately 10.1% of the company as of August 21, 2026. The stake is spread across three investment vehicles: Velan Capital Master Fund (approximately 8.0%), Horizon Fund (approximately 0.2%), and Opportunity Fund II (approximately 1.9%). The aggregate crossing of the 10% threshold makes this a significant holder disclosure. The amendment was triggered by the same equity issuance event that prompted Nijhawan's concurrent amendment.

Edesa Biotech (EDSA) entered into an underwriting agreement with Guggenheim Securities for a public offering of 3,870,500 shares of common stock plus 675,000 pre-funded warrants and 4,545,500 accompanying warrants, at a combined offering price of $5.50 per unit, with expected net proceeds of approximately $23.1 million. A 30-day overallotment option for an additional 681,825 shares was granted to the underwriters. The warrants have an exercise price of $7.50 and expire at the earlier of 18 months from issuance or 30 days after Phase 2 vitiligo topline data. This capital raise provides Edesa with runway to advance its EB05 inflammation program and conduct the Phase 2 study.

Edesa Biotech (EDSA) filed a 424B5 final prospectus for the public offering of 3,870,500 shares of common stock, 675,000 pre-funded warrants, and 4,545,500 common warrants at a combined price of $5.50 per unit. The common warrants carry an exercise price of $7.50 per share and expire at the earlier of 18 months from issuance or 30 days after the company releases topline Phase 2 vitiligo data — creating a clinical-milestone-linked expiration. At the time of filing, EDSA's stock was trading at $5.75. This prospectus finalizes the offering terms, with closing expected approximately August 21, 2026.

Edesa Biotech (EDSA) filed a preliminary 424B5 prospectus supplement on August 19, 2026, for an upcoming public offering. As a preliminary supplement, pricing and size are not yet final and subject to change. Edesa is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-related diseases; capital raises at this stage typically fund clinical trial execution and operating expenses. The final 424B5 (post-pricing) will disclose the offering size, per-share price, and use of proceeds. For a small-cap biotech, the dilutive impact of equity offerings relative to existing cash runway and pipeline milestones is the key investor consideration.

Edesa Biotech (Markham, Ontario) filed an S-3 shelf registration for future securities offerings with Lowenstein Sandler as counsel. Routine shelf registration for this clinical-stage Canadian biotech.

A significant holder filed an amended Schedule 13D on Edesa Biotech Inc. (EDSA) on June 16, 2026. Body unavailable — excerpt contains only the SEC cover-page header without filer name, stake percentage, or amended investment intent.

Edesa Biotech, Inc. entered into a Securities Purchase Agreement on June 10, 2026, for a ~$3.5 million private placement of 729,241 common shares closing on or about June 15, 2026. Most investors paid $4.69 per share; the CEO paid $5.21 per share (above the general investor price). Proceeds will fund the continued advancement of the company's vitiligo program (drug candidate paridiprubart) and general working capital. A Registration Rights Agreement requires Edesa to file a resale registration statement within 45 days of closing. The raise is a small capital injection — modest dilution — intended to extend runway for a single clinical-stage asset.